In a recent development, the Drug Regulatory Authority of Pakistan (DRAP) is embroiled in controversy as its Director of Drug Control Department, Noor Muhammad Shah, faces serious allegations of leveraging pharmaceutical companies for personal benefits. The accusations stem from revelations regarding the acquisition of a high-value vehicle allegedly financed by a pharmaceutical entity..
Sources within the regulatory body disclosed that Director Noor Muhammad Shah’s use of a white 1300 cc car, valued at over Rs. 5 million, has raised eyebrows due to indications that a pharmaceutical firm footed the bill for the vehicle. Concerns have surfaced regarding potential conflicts of interest, as Shah is purportedly affiliated with a pharmaceutical company engaged in distribution activities. It is alleged that Shah has exploited his regulatory position to pressure pharmaceutical companies into granting distribution contracts to his affiliated company.
Furthermore, insider reports suggest a pattern of coercion wherein Shah allegedly blackmails pharmaceutical companies under the guise of expediting drug approvals. The audit trail concerning the car in question reportedly confirms its procurement from a pharmaceutical company, adding credence to the accusations of undue influence and unethical conduct on Shah’s part. This development has sparked concerns about the integrity of regulatory processes within DRAP and the potential ramifications for fair competition and public health interests.
Authorities are urged to conduct a thorough investigation into these allegations to uphold transparency and accountability within the pharmaceutical regulatory framework. The outcome of this inquiry is awaited with keen interest as stakeholders seek reassurance regarding the integrity of drug regulation in Pakistan.
United Arab Emirates Dirham Exchange Rate